MiniMed 670G: a closed-loop claim needs one system evidence map

Clarus Biotech Review

The 2016 hybrid system ties sensor, algorithm, pump, user tasks, and clinical evidence together.

The original MiniMed 670G authorization is a concrete drug-delivery device case. FDA's September 28, 2016 approval concerned a hybrid closed-loop insulin-delivery system for the specified type 1 diabetes population. The system joined a glucose sensor, transmitter, control algorithm, pump, infusion set, and user workflow. [1]

## Read the word hybrid literally

The historical FDA summary explains that the system could adjust basal insulin while users still entered meal information and administered meal boluses. An automated component did not eliminate all human tasks. That boundary belongs in both the product claim and the usability plan. [1]

## The pivotal configuration and exposure matter

The pivotal program used a two-week run-in followed by a three-month study phase, with 124 enrolled subjects. A finite, selected study is useful evidence, but it does not prove zero risk during lifelong use or in every population. The device components and software configuration assessed should remain visible when a later design change is considered. [1]

## Link technical and clinical milestones

Sensor performance, algorithm behavior, infusion reliability, training, alarms, and clinical outcomes form one chain. A strong result for one component cannot replace integration evidence for the complete system. The development roadmap should identify which failures degrade measurement, which alter delivery, and which require user action.

## Adoption needs a service model

For a launch plan, assess setup, training, ongoing support, consumables, and continuity of supply. Measure sustained use and reasons for interruption instead of equating device shipment with functioning therapy. The milestone is a system that supports the intended care workflow under the authorized use conditions, with a clear evidence plan for any subsequent version.

Source adaptation: the BioClarus drug–device milestone paper informed the dependency map. This article applies it to a documented insulin-delivery system rather than repeating the women's-health example.

Sources

https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017B.pdf

Original article: https://www.clarusreview.bio/articles/drug-device-milestone-alignment